The high efficacy of Avifavir®, the first registered drug for the treatment of COVID-19, in clinical practice was recognized at the All-Russian Congress on Infectious Diseases.
Last week saw the closing of the 13th All-Russian Congress on Infectious Diseases named after academician V.I. Pokrovsky “Infectious Diseases in the Modern World: Current and Future Threats”, which was attended by many medical leaders, infectious disease scientists, epidemiologists, practitioners, and other researchers from all over the world.
And certainly, the main topic of the Congress was the fight against COVID-19, national biosafety, and fast response to biological threats. At one of the scientific sessions, Doctor of Medicine Andrey Devyatkin, who is a professor of infectious diseases at the Department of Family Medicine of the Federal State Budgetary Institution DPO “TsGMA” UD of the President of the Russian Federation and the Head of the course of infectious diseases at the Faculty of Fundamental Medicine of Moscow State University named after M.V. Lomonosov, spoke about the pathophysiological features and treatment tactics for COVID-19, as well as shared the results of a clinical trial and his personal experience of using Avifavir® against COVID-19.
Professor A.V. Devyatkin
During the scientific discussion, the specialists analyzed contraindications and warnings for the appointment of favipiravir. Professor Devyatkin emphasized that Avifavir® has shown favorable safety features in real clinical practice, both in inpatient and outpatient environments, thereby proving the data obtained during the clinical trial. He also recommended prescribing Avifavir® to patients from the very first days of the disease.
Avifavir® is the world’s first approved favipiravir-based drug against COVID-19 and the first drug against COVID-19 registered in Russia.
Chromis, a joint venture of the Russian Direct Investment Fund (